Amryt Pharma PLC (LON:AYP) CEO Joe Wiley tells Proactive the commercial-stage biopharmaceutical company's 1Q revenues rose by 30% to US$44.6mln from US$34.3mln in the corresponding period of 2019.
Wiley says its also the first time the group has become EBITDA positive, generating $4.6M in EBITDA and cash of $6.2M.